key: cord-1015769-qalficgu authors: Zhou, Hao; Tada, Takuya; Dcosta, Belinda M.; Landau, Nathaniel R. title: SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies date: 2022-02-16 journal: bioRxiv DOI: 10.1101/2022.02.15.480166 sha: 5d31adb4c4689736c39c5023d104dc35da3da621 doc_id: 1015769 cord_uid: qalficgu Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly successful in decreasing disease severity; however, the recent emergence of the heavily mutated Omicron variant has posed a challenge to this treatment strategy. The Omicron variant BA.1 has been found to evade neutralization by the Regeneron and Eli Lilly therapeutic monoclonal antibodies, while Sotrovimab and the Evusheld monoclonal antibody cocktail retain significant neutralizing activity. A newly emerged variant, Omicron BA.2, containing the BA.1 mutations plus an additional 6 mutations and 3 deletions, 3 of which lie in the receptor binding domain, has been found to be spreading with increased transmissibility. We report here, using a spike protein-pseudotyped lentivirus assay, that Omicron BA.2 is not neutralized with detectable titer by any of the therapeutic monoclonal antibodies, including Sotrovimab and the Evusheld monoclonal antibodies. The results demonstrate the difficulty of identifying broadly neutralizing monoclonal antibodies against SARS-CoV-2 and the importance of the T cell response from which immunoevasion is more difficult. The BA.2 variant of the highly mutated Omicron SARS-CoV-2 variant identified in late 2021 in patients in countries including Denmark, South Africa and India (1) and since then, in more countries including the United States. BA.2 has been found to be 1.5-fold more transmissible than the already highly transmissible BA.1 variant and is thus expected to continue to increase in prevalence (2) . The BA.2 spike protein has all of the mutations of BA.1 plus an additional 6 mutations and 3 deletions, three of which lie in the receptor binding domain (3) (Supplemental Figure 1A) . Of the monoclonal antibodies authorized by the Food and Drug Administration for emergency use (4), several were found to be largely inactive against BA.1 while the GlaxoSmithKline/Vir monoclonal antibody Vir-7831 (Sotrovimab) (5) and AstraZeneca Evusheld cocktail consisting of monoclonal antibodies AZD8895 (Tixagevimab) and AZD1061 (Cilgavimab) retain neutralizing titer, albeit with a one to two log decrease in neutralizing titer as compared to D614G (6) (7) (8) . Evusheld (Tixagevimab/Cilgavimab) is formulated for slow release to be used prophylactically primarily in immunocompromised individuals (9) . In this report, we tested the ability of the therapeutic monoclonal antibodies to neutralize the BA.2 variant, with particular interest in Vir-7831 (Sotrovimab) and Evusheld (Tixagevimab/Cilgavimab), given their ability to neutralize BA.1. Neutralizing antibody titers against the parental D614G variant, Delta, BA.1 and BA.2 were determined using spike protein-pseudotyped lentiviruses. The lentiviral pseudotype assay has been found to yield neutralizing antibody titers that are in closely agreement with those Presumably, these mutations act at a distance by affecting the conformation of the RBD spike. We report here that none of the therapeutic monoclonal antibodies tested here neutralized the Omicron BA.2 variant with titers detectable in a highly sensitive assay. Vir-7831 (Sotrovimab) and the monoclonal antibodies that constitute Evusheld Since the identification of the Omicron BA.2 variant in several countries including Denmark, South Africa and India, the variant has been identified in infected individuals in additional countries and mathematical models predict that its increased transmissibility will result in its continued increase in prevalence (2) . While monoclonal 7 antibody therapy has been highly effective at preventing hospitalization and death, the emergence of the Omicron variant poses a major threat to the efficacy of current treatments. As BA.2 prevalence increases, current monoclonal antibodies may become less effective for the treatment of COVID-19. Therapies that target BA.2 and potential future variants that may emerge are therefore of great importance. The findings presented here demonstrate the difficulty of finding a pan-neutralizing monoclonal antibody against SARS-CoV-2. Our findings support the importance of small molecule drugs such as Molnupiravir (12) and Nirmatrelvir (13) that act on viral targets outside of the highly mutable spike protein (14) . They also provide further rationale to protect against severe disease by vaccination which induces cross-reactive antibodies and T cell responses against spike protein epitopes that are not mutated in the Omicron variants. 8 The SARS-CoV-2 spike expression vector (Omicron BA.2) was generated by overlap extension PCR with the two fragments amplified with external primers containing a Kpn-I and Xho-I sites and cloned into pcDNA6. Spike expression vectors with the individual mutations of the Omicron BA.2 RBD were generated by overlap PCR mutagenesis using the D614G spike expression vector pcCOV2.Δ19.D614G as a template. 293T, ACE2.293T and Vero cells were grown in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum at 37°C. SARS-CoV-2 spike protein pseudotyped lentivirus stocks were produced by cotransfection of 293T cells with pMDL Gag/Pol vector, plenti.GFP.nLuc and spike protein expression vectors which deleted 19 amino acid from cytoplasmic tail. After 2 says transfection, supernatants were harvested and concentrated by ultracentrifugation. The viruses were normalized for reverse transcriptase (RT) activity. Monoclonal antibodies were serially diluted (two-fold) and incubated with pseudotypes (MOI=0.2 on target cells). After 30 minutes incubation, the virus was added to target cells in a 96 well culture dish. After 2 days of infection, infectivity was developed by 9 Nano Glo substrate and luminescence was read in an Envision 2103 microplate luminometer. All samples were tested in duplicate. Data were analyzed using GraphPad Prism 8 software. Analyses of the structures of the SARS-CoV-2 spike protein with antibody Variant: What You Need to Know Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households Mutational and phylogenetic analyses of the two lineages of the Omicron variant Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Res Sq Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2 phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Cell Rep The work was funded by grants from the NIH to N.R.L. (DA046100, AI122390 and AI120898). The authors declare no conflicting financial interests.